Ani Pharmaceuticals (ANIP) Current Deferred Tax Assets (2014 - 2015)

Ani Pharmaceuticals (ANIP) reported Current Deferred Tax Assets of $8.3 million for Q3 2015, up 3.34% sequentially from $8.0 million in Q2 2015.

Ani Pharmaceuticals (ANIP) Current Deferred Tax Assets (2014 - 2015) Analysis & Trends

Ani Pharmaceuticals (ANIP) has 2 years of Current Deferred Tax Assets data on file, last reported at $8.3 million in Q3 2015.

For the quarter ending Q3 2015, Current Deferred Tax Assets changed N/A year-over-year to $8.3 million; the trailing twelve-month figure through Sep 2015 stood at $8.3 million (changed N/A YoY), and the FY2014 full-year result was $7.6 million, changed N/A from the prior year.
Current Deferred Tax Assets climbed to $8.3 million in Q3 2015, from $8.0 million in the prior quarter.
In the past five years, Current Deferred Tax Assets ranged from a high of $8.3 million in Q3 2015 to a low of $7.6 million in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Ani Pharmaceuticals	1.64 Bn	1.33 Bn	143.88 Mn

Download Data